Why the study?
Does once-daily sustained-release oxprenolol reduce anginal attacks and glyceryl trinitrate consumption in patients with angina pectoris previously on multi-dose beta-blockers?
Does once-daily sustained-release oxprenolol reduce anginal attacks and glyceryl trinitrate consumption in patients with angina pectoris previously on multi-dose beta-blockers?
Once-daily sustained-release oxprenolol reduces tablet burden while maintaining or improving symptom control in patients with angina pectoris.
Answers are grounded in this paper and cite their sources.
Supports once-daily dosing to ease tablet burden in angina; hypothesis-generating pending randomized confirmation.
One hundred and two patients with angina pectoris under treatment with beta-receptor antagonists prescribed on a multi-dose basis were openly switched to treatment with once-daily sustained-release oxprenolol (160 mg per tablet). Eighty-eight patients were successfully managed on once-daily oxprenolol and 70% achieved significant benefit with a single morning dose of 160 mg. The mean number of anginal attacks and the mean glyceryl trinitrate consumption were both significantly reduced. It is concluded that once-daily treatment with oxprenolol in sustained-release form offers the advantage of reduced tablet ingestion without symptomatic detriment in the management of angina pectoris.
No takes yet. Share an insight, caveat, or question.
W A Forrest (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: